Designing a GLP-1 Clinical Trial in 2026: What the Pipeline Data Tells Us About Protocol Strategy
GLP-1 receptor agonists have moved beyond diabetes and obesity. With 34 active pipeline candidates spanning 14 therapeutic indications — from Alzheimer’s to addiction to autoimmune disease — protocol designers are facing a set of challenges that didn’t exist 18 months ago. We analyzed the full GLP-1 trial landscape using data from ClinicalTrials.gov, openFDA, and PubMed…
